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I. SUMMARY 
Over the last decade, it became clear that the tumor stroma plays an active role in 
the process of tumor progression, by interacting with the transformed cells and 
providing a permissive microenvironment for malignant growth. The tumor 
microenvironment is a complex system comprised of extracellular matrix and the 
different cell populations within it. The extracellular matrix that surrounds solid 
tumors is very different from the healthy counterpart. Various proteins are 
upregulated in the tumor stroma, among them two members of the tenascin family, 
tenascin-C and tenascin-W. Similar to tenascin-C, tenascin-W is mainly expressed 
during development and in the adult its expression is restricted. Tenascin-W has 
previously been found in the stroma of breast cancer and colon carcinoma. We have 
extended the range of human solid tumors that express tenascin-W to brain tumor, 
melanoma, lung and kidney carcinoma, and we show that tenascin-W is not 
detectable in the corresponding normal tissues. Moreover, we demonstrate that 
tenascin-W is often localized in close proximity with tumor blood vessels. Our in vitro 
studies reveal that tenascin-W has an antiadhesive, pro-migratory effect on a variety 
of cultured cells, in particular endothelial cells. We therefore postulate a pro-
angiogenic role for tenascin-W in tumors. Due to its specific expression in solid 
tumors, we propose tenascin-W as a tumor biomarker. 
We also report that tenascin-W is upregulated during osteogenic differentiation of 
human bone marrow derived mesenchymal stem cells, fitting with its expression 
during bone development reported in chicken and mice. 
In order to shed light on the mechanism of regulation, we studied the human 
tenascin-W promoter. We found a putative GATA binding site in this promoter that 
enhances reporter gene activity when deleted or mutated. We used a labeled DNA 
probe harboring the binding site in pulldown experiments, followed by mass spec 
identification of the binding proteins. We identified four members of the NuRD 
repressor complex among the proteins pulled down. The specific binding of the 
CHD4 core component of the complex to the human tenascin-W promoter was 
confirmed by chromatin immunoprecipitation. We therefore speculate that the 
human tenascin-W gene is silenced by NuRD-mediated chromatin remodeling.
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II. INTRODUCTION 
II.1 – The importance of tumor microenvironment 
Carcinogenesis is a multistep process characterized by the progressive acquisition 
and accumulation by cancer cells of genetic and epigenetic alterations that 
eventually allow them to escape the controls and constraints of tissue homeostasis, 
proliferating and disseminate (1–4). According to Hanahan and Weinberg (1, 5), the 
six traits (“hallmark”) common to all types of cancer cells and that together allow 
malignant growth are: (I) ability to sustain chronic proliferation, (II) resistance to 
growth suppressive signals, (III) resistance to cell death, (IV) achieved unlimited 
replicative potential, (V) induction of angiogenesis, and (VI) ability to invade the 
surrounding tissue and metastasize. A great deal of research has been carried out 
to unveil the molecular mechanisms underlying malignant growth. The knowledge of 
the signaling pathways aberrantly activated in cancer led to discovery of better 
drugs and new therapeutical approaches (6). Nevertheless, due to the complex 
nature of the disease and its intrinsic heterogeneity, therapeutic approaches that 
focused exclusively on cancer cells are insufficient to effectively control the 
pathology. 
Over the last years, new evidences of the deep influence that the surrounding 
stroma exerts on any aspect of carcinogenesis shifted the attention of the cancer 
biology community on the tumor microenvironment (7, 8). The emerging view is 
tumor as a complex tissue, in which neoplastic cells interact with different neighbor 
cell types and by these interactions the outcome of tumor progression is determined 
(9, 10).  
The tumor microenvironment is a heterogenic system comprised by extracellular 
matrix and the cellular populations within it (11) (Fig. II.1). The non-tumoral cell 
populations present in the tumor stroma include inflammatory cells (12), vascular-
associated cells like endothelial cells and pericytes (13), and activated fibroblasts 
(14, 15). 
Many solid tumors exhibit a very different profile of extracellular matrix protein in 
their stroma, when compared to their normal counterparts (16). A number of 
proteins is upregulated specifically in solid tumors, like tenascin-C (17) and 
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fibronectin (18). As well as its composition, the mechanical properties of the 
extracellular matrix also have an impact on its function, as the stiffness of tumor 
stroma stimulate cancer cells growth and invasion (19).  
A consequence of acknowledging the role of tumor microenvironment on the 
process of carcinogenesis is the development of new therapeutical strategies, that 
target the tumor-permissive microenvironment rather than the transformed epithelial 
cells (20–22).  
 
 
 
 
Figure II.1 – Changes to the normal microenvironment promote tumor invasion. Activation of 
carcinoma-associated fibroblasts and induction of an inflammatory infiltrate lead to release of pro-
angiogenic factors. Development of an altered extracellular matrix (ECM) leads to tumor-specific 
interactions with tumor cells and enhance invasion (16)  
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II.3 – Aim of this work 
Tenascin-W was the fourth tenascin to be discovered, and most likely there are no 
other members of the tenascin family in the genome (23). Being “the last tenascin”, 
tenascin-W remains poorly understood in its functions and regulation.  
The primary goal of this work is to further deepen the knowledge of tenascin-W. We 
will study its expression pattern in different human tumors, to test whether tenascin-
W is a suitable tumor biomarker. In order to understand tenascin-W functions, we 
will investigate its effect on different types of cells in culture, employing a wide panel 
of in vitro assays. Furthermore, the tenascin-W promoter will be identified and 
described. From its characterization we hope to shed light on the gene regulatory 
mechanisms controlling its expression.    
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Abstract  
Background 
Tenascins are large glycoproteins found in the extracellular matrix of many 
embryonic and adult tissues. Tenascin-C is a well-studied biomarker known for its 
high overexpression in the stroma of most solid cancers. Tenascin-W, the least 
described member of the family, is highly expressed in the stroma of colon and 
breast tumors and in gliomas, but not in the corresponding normal tissues. Other 
solid tumors have not been analyzed. The present study was undertaken to 
determine whether tenascin-W could serve as a general cancer-specific 
extracellular matrix protein in a broad range of solid tumors. 
Methods 
We analyzed the expression of tenascin-W and tenascin-C by immunoblotting and 
by immunohistochemistry on multiple frozen tissue microarrays of carcinomas of the 
pancreas, kidney, lung as well as melanomas and compared it to healthy tissues.  
Results 
From all healthy adult organs tested, only liver and spleen showed detectable levels 
of tenascin-W, suggesting that tenascin-W is absent from most human adult organs 
in normal, non-pathological conditions. In contrast, tenascin-W was detectable in the 
majority of melanomas and their metastases, as well as in pancreas, kidney, and 
lung carcinomas. Comparing lung tumor samples and matching control tissues for 
each patient revealed a clear overexpression of tenascin-W in tumor tissues. 
Although the number of samples examined is too small to draw statistically 
significant conclusions, there seems to be a tendency for increased tenascin-W 
expression in higher grade tumors. Interestingly, in most tumor types, tenascin-W is 
also expressed in close proximity to blood vessels, as shown by CD31 co-staining of 
the samples. 
Conclusions 
The present study extends the tumor biomarker potential of tenascin-W to most 
solid tumors and shows its accessibility from the blood stream for potential 
therapeutic strategies.  
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Background 
During recent years increasing evidence has emerged showing that the 
microenvironment plays a prominent role in determining tumor behavior [1-4]. Tumor 
progression is influenced and controlled by activation of nearby stromal cells, 
including fibroblasts, endothelial cells and macrophages. In their activated states, 
these cells modulate and reorganize the extracellular matrix and create a congenial 
microenvironment for the tumor cells. Accepting an active role of the 
microenvironment for tumor progression, it will be important to consider how the 
activated tumor stroma can be harnessed for clinical benefit. Extracellular matrix 
proteins specifically expressed in tumor stroma could thus represent promising 
predictive/diagnostic biomarkers or target molecules for therapeutics.  
Tenascin-C and tenascin-W are two members of the tenascin family of large 
extracellular matrix glycoproteins whose functions are associated with cellular 
mechanisms such as adhesion modulation, motility, proliferation and differentiation 
[5]. Both proteins share highest expression during embryonic development and 
reduced and very restricted expression in the adult organism [6]. Tenascin-C, the 
best-described family member, reappears during pathological conditions such as 
cancer, inflammation or wounds [7,8]. Soon after its initial identification, tenascin-C 
was proposed as a stromal marker in breast cancer [9]. Since then, many more 
studies have been performed and tenascin-C expression shows predictive value for 
local tumor recurrence and metastatic dissemination in many aggressive cancers 
(for reviews see [2,10,11]. Its cancer-specific expression has been exploited to 
make tenascin-C a promising target for different anti-cancer therapies, including the 
delivery of cytokines or radionuclides to the tumor using tenascin-C-specific 
monoclonal antibodies  [12-14] or aptamers [15,16].  
Similar physiological expression patterns as well as shared functions of tenascin-W 
with tenascin-C prompted us to investigate the presence of the newest tenascin 
family member, tenascin-W in different human cancers. Tenascin-W expression was 
detected in a large majority of human breast tumors, showing enrichment in low-
grade compared to high-grade tumors [17]. In colorectal cancer, tenascin-W 
expression was restricted to the tumor-associated microenvironment, while the 
protein was not detectable in the corresponding healthy tissue [18]. In brain tumors, 
all glioma subtypes tested (oligodendroglioma, astrocytoma and glioblastoma) were 
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enriched in tenascin-W in comparison to healthy control brain tissues [19]. 
Noticeably, in all glioblastoma samples analyzed the localization of tenascin-W was 
perivascular [19].  
Encouraged by the highly tumor-specific expression of tenascin-W in breast, colon, 
and brain tumors, we now extended our expression study to many more types of 
solid tumors. We show here, that tenascin-W expression displays an even higher 
specificity for cancer-related microenvironments than tenascin-C. Hence, tenascin-
W represents a novel attractive cancer biomarker of broad potential for tumor 
detection, prediction and targeting approaches.   
 
Results 
Tenascin-W is not detectable in most adult organs 
To compare tenascin-W and tenascin-C protein expression in normal healthy adult 
humans, we analyzed tissue extracts from ten different organs and analyzed their 
protein content on western-blots (Fig. 1A). Only in spleen and liver very faint bands 
for tenascin-W were observed. In agreement with our recent observations, we did 
not detect any tenascin-W in healthy human breast, colon and brain tissues [17-19]. 
Furthermore, normal uterus, lung, heart, pancreas and kidney appeared devoid of 
tenascin-W, too. In contrast, tenascin-C was detectable in all organs tested, except 
for normal breast and heart tissues. As has been described earlier [17-20], we 
detected different tenascin-C isoforms in our immunoblot analysis of normal human 
tissues, although in pancreas, kidney, and colon only the lower tenascin-C isoform 
was observed.  
Our earlier studies showed tenascin-W overexpression in human breast, colon, as 
well as brain tumors [17-19]. To obtain a more complete neoplasia-associated 
expression profile of tenascin-W, we tested here whether tenascin-W enrichment 
also can be found in solid tumors originating from other organs.  
 
Tenascin-W is overexpressed in pancreas carcinomas 
Pancreas carcinoma extracts from nine different patients were analyzed by western-
blotting for their expression of tenascin-W and tenascin-C (Fig. 1B). In contrast to 
healthy pancreas tissue (Fig. 1A), most pancreas carcinomas (7/9) did express 
detectable amounts of tenascin-W. Among the seven tenascin-W positive tumors, 
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four contained very high levels of tenascin-W (patients # 1, 2, 5, and 6) and three 
samples displayed moderate levels (patients # 7-9). Tenascin-C was observed in 
most of the samples varying from barely detectable (patients # 1, 7-9) to 
intermediate (patients # 4, 5) and to high levels (patient # 2, 6). The levels of 
tenascin-W and tenascin-C did not correlate and in the sample from patient #1 with 
the highest tenascin-W level tenascin-C was barely detectable (Fig. 1B). While in 
normal pancreas tissue only a low molecular-weight isoform of tenascin-C was 
detectable (Fig. 1A), pancreas tumor tissues expressed additional high isoforms 
(Fig. 1B). So far we do not have any evidence for the existence of tenascin-W 
splice-variants (Fig.1) 
 
Tenascin-W is overexpressed in kidney tumors 
Tenascin-W and tenascin-C expression was analyzed by western-blotting in kidney 
carcinoma samples (Fig. 1C). Tenascin-W was detected in most cases (6/9): 2 out 
of 9 expressed very high levels of tenascin-W, 4 moderate levels and in 3 samples 
tenascin-W was not detectable. Tenascin-C was also observed in most samples 
(7/9), but again could not be correlated with tenascin-W expression. 
In parallel, a frozen kidney tumor TMA (n=84) was stained by immunohistochemistry 
for expression of tenascin-W and tenascin-C. For each tumor sample, we quantified 
expression levels of both tenascins and classified them into the following 4 
categories with respect to their tenascin expression: absent, low, moderate and 
high, as described in Materials and Methods (Fig. 2A,B). Although we could not 
detect tenascin-W by western-blot in healthy kidney tissue (Fig. 1A), 
immunohistochemical analysis revealed slight, but clearly visible expression of 
tenascin-W in most of the control kidney samples (see representative image in Fig. 
2C). As can be seen in the pie chart more than half of the tumors (56%) expressed 
easily detectable expression of tenascin-W (i.e. moderate or high) while for 
tenascin-C this was the case for 92% of all kidney tumors on the TMA (Fig. 3A). 
Interestingly, tenascin-W was never in a higher expression category than tenascin-C 
as no number appears in the upper right “triangle” of the table in Fig. 2B. Using a 
numerical score for each category (see Materials and methods) the average scores 
for each tumor type was calculated. The average scores for the levels of tenascin-W 
and tenascin-C of the 70 clear cell carcinomas were 1.7±0.10 and 2.69±0.07 
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respectively, for the 6 papillary carcinomas 1.33±0.33 and 2.67±0.33, for the 6 
chromophobe carcinomas 1.17±0.31 and 2±0.26 and for the 2 oncocytoma 1 and 1. 
This suggests that the tenascin levels may correlate with the tumor type. However, 
more samples would be necessary to strictly proof such a correlation. 
 
Tenascin-W is overexpressed in melanomas 
A frozen TMA containing 34 melanoma samples including primary tumors and 
metastases was stained by immunohistochemistry for tenascin-W and tenascin-C. 
Each individual tumor staining was quantified and categorized as described above 
(Fig. 3). Representative pictures for each tenascin-W group for each type of sample 
are shown in parallel to the matching tenascin-C stainings of the same tumor 
patient. Fig.3A shows stainings of primary tumors (PT), Fig. 3B metastases (MET) 
and Fig. 3C lymph node metastases (LN-MET). These tumor samples can be 
compared to the healthy skin tissue shown in Fig. 3E. Tenascin-W was  not 
detectable in any normal skin sample whereas tenascin-C was observed in the 
dermis of three out of six samples (Fig. 3D), just below the basement membrane 
underlying the basal epidermal cell layer, as has been described previously [21]. A 
summary of all stainings is presented in a table (Fig. 3D). It shows that 60% (3 out 
of 5) of primary melanomas (PT) had moderate or high expression of tenascin-W, 
while tenascin-C was detectable in all of the primary tumor samples with a staining 
classified at least as moderate. In samples obtained from metastasis from diverse 
locations (i.e. spleen, lung, skin), tenascin-W had moderate staining in 25% (2 out of 
8) of the samples, while tenascin-C is strongly expressed in 87% (7 out of 8) of 
samples. Similar proportions were observed in samples of lymph node metastasis: 
38% of samples (8 out of 21) showed moderate or high tenascin-W, while 71% (15 
out of 21) of the samples displayed at least moderate tenascin-C staining. Similar to 
the kidney TMA analysis, tenascin-W expression was never found in a higher 
expression category than tenascin-C. It is noteworthy that the only two samples in 
which tenascin-W is classified in the highest category of expression are both lymph 
node metastases. 
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Tenascin-W is overexpressed in lung tumors 
In our analysis of lung tumors we stained a total of 95 tumor samples for the 
presence of tenascin-W and tenascin-C. Immunohistochemical analysis showed that 
tenascin-W was detectable in all 95 tumor samples (Fig. 4). For 21 of these samples 
we were able to analyze matching adjacent normal lung parenchyma that had been 
biopsied at least 3cm away from the edge of the tumor. These corresponding 
healthy tissues did not display any detectable tenascin-W expression demonstrating 
that tenascin-W expression was restricted to tumor associated stroma. In contrast, 
tenascin-C was also present in the normal lung tissue adjacent to the tumors. In 
many of the lung tumor samples, we could observe a very typical pattern of 
tenascin-W expression:  a fibrous staining (parallel lines forming bundles) 
surrounding nests of tumor cells (Fig. 4C, #9297). This suggests that tenascin-W is 
mainly expressed by stromal cells surrounding the carcinoma cells. Quantification of 
the stained area of tumors from an extended cohort of patients (n=95) revealed that 
tenascin-W expression was never completely absent in any of the tumors, a feature 
shared by tenascin-C (Fig. 4A,B). 65% of the tumor samples had at least moderate 
tenascin-W expression while for tenascin-C this was the case for 92% of the 
samples. With the exception of 5 cases, tenascin-C was in the same or higher 
expression category as tenascin-W (Fig. 4B). However, since tenascin-C expression 
levels in control lung tissues have been much higher than tenascin-W levels, 
tenascin-W seems to be much more tumor-specific than tenascin-C in the case of 
the lung.  Information about the stage of the tumor was available for 69 of the 95 
samples included in the present study. Interestingly, the average level of tenascin-W 
seems to correlate with tumor grade: the two grade I tumors both have a tenascin-W 
score of 1 (tenascin-C score is 2); grade II tumors (n=19) have an average tenascin-
W score of 1.74±0.15 (tenascin-C: 2.47±0.18); tumors with grade intermediate 
between II and III (n=6) have an average score of 1.83±0.30 (tenascin-C: 
2.33±0.33); grade III tumors (n=27) have average score of 2.18±0.17 (tenascin-C: 
2.55±0.11); finally, the average tenascin-W score of grade IV tumors (n=15) is 
2.07±0.23 (tenascin-C: 2.6±0.16). Although the number of samples examined is too 
small to draw statistically significant conclusions, there seems to be a tendency for 
increased tenascin-W expression in higher grade tumors. 
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Tenascin-W is expressed around blood vessels 
Our previous study on tenascin-W expression in brain tumors showed for the first 
time that tenascin-W is expressed around blood vessels of gliomas [19]. Here, we 
investigated whether this observation holds true as well for tumors originating from 
other organs. For this purpose, we co-stained lung and kidney tumors for tenascin-
W and CD-31, an established blood vessel marker (Fig. 5). In most of the tumor 
samples a prominent co-localization between tenascin-W and blood vessels (CD31 
positive) was observed. These results confirmed our earlier study in brain tumors 
and suggest that tenascin-W is often expressed adjacent to blood vessels, 
independently of vessel size. Tenascin-W co-localization with blood vessels was 
also observed in additional analyses of colon, breast, ovarian and prostate tumors 
(data not shown). Thus, the presence of tenascin-W around tumor blood vessels 
seems to be widespread. 
 
Discussion 
Recent studies on tenascin-W have identified this protein as a candidate biomarker 
for breast tumors [17], colorectal tumors [18] as well as gliomas [19]. In addition to 
these tumor sites, we report in the present study that tenascin-W is also prominently 
expressed in melanomas, pancreas, kidney and lung carcinoma samples. 
Importantly, we were not able to detect it in the normal corresponding organs, 
except for a slight presence in normal kidney. The tumor-specific expression was 
especially striking for the lung for which we had clinical material available to 
compare 21 tumors with matching healthy tissue fragments of the same patient. All 
of these 21 tumor/non-tumor pairs revealed a specific tumor-restricted tenascin-W 
staining, whereas the non-tumor samples were all negative. Therefore, tenascin-W 
might be a diagnostic marker for lung cancer and its expression seems to increase 
with tumor grade. Tenascin-W was also expressed in the majority of kidney tumors 
tested. Although western-blot analysis did not reveal the presence of tenascin-W in 
a kidney control tissue extract, we could observe a slight tenascin-W staining by 
immunohistochemistry in all 10 control kidney tissues analyzed. This result is in 
agreement with our previous observation that tenascin-W can be found in the kidney 
of adult mice [22]. Tenascin-W and tenascin-C levels appeared in average to be 
higher in clear cell carcinomas than in papillary or chromophobe renal cell 
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carcinomas and lowest in oncocytoma, suggesting a correlation with severity of the 
disease. In addition, we could also observe overexpression of tenascin-W in ovarian 
cancer samples and in prostate tumors (data not shown). Our general observation 
that tenascin-W is overexpressed in the stroma surrounding many tumors, but 
absent in most corresponding control tissues, qualifies tenascin-W as a tumor 
biomarker. This is less the case for tenascin-C, as tenascin-C overexpression has 
been correlated with various conditions other than cancers, such as inflammation, 
infection, asthma, fibrosis and wound healing (for reviews see [7,8]).  
So far, tenascin-W overexpression has been exclusively described in the context of 
tumorigenesis and osteogenesis [6], which suggests that it might be a more specific 
tumor marker than tenascin-C. In the case of tenascin-C there remains the 
possibility that certain splice variants could be more tumor-specific than others and 
thereby provide a good target as well [23,24]. This is also the case for another 
ubiquitous extracellular matrix protein, namely fibronectin, which was shown to have 
cancer-specific splice variants which can be used as targets for antibody-mediated 
therapy in human patients [25,26]. It remains to be seen whether tenascin-W is 
elevated in sera of patients suffering from solid tumors other than breast and colon, 
where elevated tenascin-W serum levels have been described [18]. The same might 
be the case for pancreas, kidney or lung tumor patients as these tumors show 
strong tenascin-W staining in situ.   
Here we have found that tenascin-W is expressed in close vicinity of blood vessels 
in a wide range of tumors including kidney, colon, breast, ovary and prostate 
tumors.  In another study we have found that tenascin-W acts as a pro-angiogenic 
factor in vitro [19]. Therefore, we can speculate that in vivo tenascin-W could act on 
tumor endothelial cells, influencing their migration and thus contributing to the 
expansion of the endothelial network. What triggers tenascin-W expression in the 
tumor stroma and more particularly next to the blood vessels remains to be 
established, but it likely involves complex tumor-microenvironment interactions.  
In several tumors, there is now compelling evidence that the capacity for a tumor to 
grow and proliferate lies in a small fraction of cells, called cancer stem cells (CSC) 
or cancer initiating cells. Similar to normal stem cells, CSC have the ability to self-
renew and to differentiate into a variety of proliferating cells that make up the tumor 
mass. It can be speculated that maintenance of CSCs depends upon a specific 
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stem cell niche microenvironment that protects CSCs from therapeutics. Therefore, 
targeting these microenvironments might result in more effective treatments of 
cancers. Interestingly, tenascin-C has been reported to maintain an ABCB5+ 
subpopulations of melanoma-initiating cells thereby promoting melanoma 
progression [27]. Moreover, for several cancers, cancer stem cell populations reside 
in perivascular niches as their preferred microenvironment [28-31]. Given the tumor-
specific overexpression of tenascin-W and its perivascular staining pattern, one can 
speculate about a role for tenascin-W in maintaining CSC’s and offering them a 
congenial niche.    
The present study extends the potential of tenascin-W as biomarker to a large 
variety of solid tumors. Given both its specific expression in tumors compared to 
corresponding healthy tissues and its proximity to tumor blood vessels (making it 
easily accessible via the bloodstream) we propose tenascin-W as a good candidate 
for selective delivery of anticancer medicine. 
 
Methods 
Tissue samples 
Protein extracts from uterus, spleen, liver, lung, cerebrum and heart control tissues 
were from autoptic material obtained from the Institute of Pathology from the 
University Hospital of Basel, Switzerland. Pancreas, kidney and colon control whole 
tissue homogenates were purchased from BioCat GmbH (Heidelberg, Germany). 
Protein extracts from breast, pancreas and kidney tumors were obtained from the 
Institute of Pathology of the University Hospital of Basel, Switzerland. All extracts 
were prepared as described before [17]. 
Melanomas, kidney and lung tumors used for immunohistochemistry were part of 
frozen tissue microarrays (TMA) obtained from the Institute of Pathology of the 
University Hospital of Basel, Switzerland. References for their construction can be 
found elsewhere [17]. The melanoma TMA was constructed from frozen tissue 
samples of 34 malignant melanomas (5 primary tumors, 8 metastases from different 
organs and 21 lymph node metastases) and 6 control healthy cutaneous tissue 
samples. The kidney TMA was constructed from frozen tissue samples of 84 kidney 
tumors (70 clear cell renal carcinomas, 6 papillary renal carcinomas, 6 
chromophobe renal cell carcinomas and 2 oncocytoma) and 10 healthy control 
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kidney tissues. The lung TMA was constructed from frozen tissue samples of 74 
lung tumors (40 squamous carcinomas, 19 adenocarcinomas and 15 
undifferentiated carcinomas). Additional lung tumor samples were obtained from the 
University Hospital of Tours, France. The latter collection contained frozen tissues 
from matched samples of tumor and adjacent non-tumor tissue. They were obtained 
from 21 patients who had undergone lung cancer resection as their primary therapy 
without preoperative radiation or chemotherapy. These non-small cell lung cancers 
consisted of 10 adenocarcinomas, 10 squamous carcinomas and 1 undifferentiated 
carcinoma. The non-malignant tissue samples were taken from sites at least 3 cm 
away from the edge of the tumor. The histological diagnosis was determined by two 
pathologists.   
Studies were performed in compliance with the Declaration of Helsinki and in 
accordance with the guidelines of the ethical committee of the University of Basel, 
Switzerland or with French bioethical regulations.  
 
Western blot analysis 
Tissue samples were thawed on ice, minced and homogenized in RIPA lysis buffer. 
After determination of protein concentration by a Bio-Rad Protein assay, samples 
were separated by SDS-PAGE (6%) and electroblotted to polyvinylidene difluoride 
membranes. Equal loading and transfer of protein was confirmed by staining the 
membranes with amidoblack. After a blocking step in 5% milk powder in Tris-
buffered saline (TBS), membranes were incubated overnight with the rabbit 
polyclonal antiserum pAb (3F/4) raised against human tenascin-W (1:750), the 
mouse monoclonal antibody B28-13 raised against human tenascin-C (1:100), the 
V-9131 mouse monoclonal antibody against vinculin (1:2000; Sigma). After 
incubation for 1 hour with anti-mouse IgG or anti-rabbit IgG coupled to horseradish 
peroxidase, blots were developed using Super Signal (Pierce) for tenascin-C and 
tenascin-W and ECL reagent (GE Healthcare) for vinculin followed by exposure to 
Kodak BioMax MR Films.  
 
Immunostaining and quantification 
Chromogenic and fluorescent detections were performed on 9 µm-thick cryosections 
using the Discovery XT automated stainer (Ventana Medical Systems) with standard 
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and customized procedures, respectively. Frozen tissue slides were dried for 1 hr at 
room temperature, fixed for 10 min at 4°C in cold acetone and then introduced into 
the automate. For chromogenic stainings, slides were incubated for 1 hr at 37°C 
with the mouse monoclonal 56O antibody raised against human tenascin-W 
(1:1000) [18] or the B28-13 anti-tenascin-C antibody (1:1000). They were then 
treated for 32 min at 37°C with a biotinylated anti-mouse secondary antibody (1:200; 
Jackson Immunoresearch laboratories 715-065-150) and developed with DAB Map 
detection kit (Ventana). Counterstainings were obtained with hematoxylin and bluing 
reagent (Ventana). For immunofluorescent stainings, slides were incubated for 1 
hour at 37°C with anti-tenascin-W mAb 56O (1:50), anti-tenascin-C mAb B28-13 
(1:50) or anti-CD31 (1:200; M0823, DAKO). They were then treated for 32 min at 
37°C with Alexa Fluor 647 donkey anti-mouse IgG and Alexa Fluor 488 goat anti-
rabbit IgG secondary antibodies (1:200; Invitrogen A31571 and A11029, 
respectively), carefully rinsed by hand and mounted with prolong Gold reagent 
(Invitrogen). Pictures were either acquired with a Mirax Slidescanner (Zeiss AG, 
Zurich, Switzerland) using a 20×/0.5 lens (0.2 μm/pixel) and converted into standard 
TIFF format or with a Nikon Eclipse 80i microscope equipped with a Leica DFC420 
color camera. For quantification, the area of the section stained by tenascin-W or 
tenascin-C was measured using ImageJ by setting the color threshold as follows: 
hue 0-40, saturation 50-255, luminosity 0-200. The resulting area was divided by the 
total area of the section to obtain a percentage. The samples were then classified in 
four categories according to the amount of staining: 0%, no staining; 1%-10%, low; 
11%-40%, moderate; >40%, high. In order to compare tumor type or grade with the 
tenascin stainings a numerical score was assigned to each category (no staining=0, 
low=1, moderate=2, and high=3) and the average scores for each tumor type/grade 
was calculated. 
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Figure legends 
Figure 1  
Immunoblot analysis of tenascin-W and tenascin-C protein expression in various 
healthy human adult organs (A), in pancreas carcinomas (B) and in kidney 
carcinomas (C). Blots were also probed for vinculin (VCL) to check equal loadings of 
protein samples. A: Note the presence of tenascin-C in all but one organ tested, 
whereas tenascin-W is undetectable in the majority of organs. The last two lanes 
contain 25ng of purified tenascin-C (TNC) or tenascin-W (TNW), respectively. B: 
Extracts from nine pancreas carcinomas were tested for their tenascin-W and 
tenascin-C levels. Note that tenascin-W is expressed in most of the pancreas 
carcinomas tested. C: Extracts of nine kidney carcinomas were tested for their 
tenascin-W and tenascin-C expression. Tenascin-W was observed in most of the 
kidney carcinomas tested. 
 
Figure 2 
Immunohistochemical analysis of kidney tumor samples. Eighty-four kidney tumor 
samples, spotted on a frozen TMA were stained for of tenascin-W and tenascin-C. 
The area of the section stained for tenascin-W or tenascin-C was quantified and the 
samples were classified in four categories (absent, low, moderate and high) as 
described in Materials and Methods. The percentage of tumors classified in each 
category for tenascin-W and tenascin-C is shown as pie charts (A). A double-entry 
table details how many tumors show each combination of tenascin-W/tenascin-C 
expression (B). Top panel in C shows normal kidney tissues stained for tenascin-W 
(left) and tenascin-C (right). Representative pictures of tumors of each category are 
shown for tenascin-W (C, left panel) with the corresponding tumor area stained for 
tenascin-C in parallel (C, right panel). Scale bars = 200 µm. 
 
Figure 3  
Immunohistochemical analysis of malignant melanoma samples. Thirty-four 
melanoma tissues from a frozen TMA were stained for their expression of tenascin-
W and tenascin-C. The area of the section stained for tenascin-W or tenascin-C was 
quantified and the samples were classified as in Figure 2. Representative pictures of 
each tumor type are grouped in different panels: A) primary tumors (PT), B) 
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metastases (MET), C) lymph node metastases (LN-MET). From top to bottom, 
pictures in the left column of each panel represent increasing scores of tenascin-W 
from absent, low, moderate to high (only in panel C) with the corresponding tumor 
stained for tenascin-C in the right column of each panel. Panel E shows normal skin 
tissue stained for tenascin-W (left) and tenascin-C (right). Scale bars = 200 µm. 
Table D summarizes the distribution of the scores for each tenascin in the different 
groups.  
 
Figure 4 
Immunohistochemical analysis of lung tumor samples. Ninety-five lung tumor 
sections were stained for their expression of tenascin-C and tenascin-W and 
classified as described in Figure 2. The percentage of tumors classified in each 
category for tenascin-C and tenascin-W is shown as pie charts (A). A double-entry 
table details how many tumors show each combination of tenascin-W/tenascin-C 
expression (B). Twenty-one pairs of matching lung tumor/control lung tissue 
samples were stained for their expression of tenascin-W and tenascin-C. 
Representative stainings are shown: sample #5162 is from an adenocarcinoma, 
#9297 is from a squamous carcinoma and #4713 is from an undifferentiated 
carcinoma (C). Scale bars = 200 µm. 
 
Figure 5 
Double immunofluorescence staining of tenascin-W and CD31 in kidney tumors 
(upper panel) and lung tumors (lower panels). Tumor cryosections were used for 
fluorescent detection of tenascin-W (red), CD31 (green) and DAPI (blue). Each row 
represents a different tumor sample. Scale bars = 50 µm. 
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III.3 Unpublished results 
 
III.3.1 – Tenascin-W gene is repressed by the NuRD complex 
III.3.1.1 – The genomic location of the human tenascin-W gene 
The human tenascin-W gene is located on chromosome 1 (chr1:175,036,994-
175,117,202) and consists of 19 exons. The first 76bp-long untranslated exon is 
followed by a second exon that contains the start codon (Fig.III.1A). Figure 1B 
represents the genomic location of the 5’ region of the tenascin-W gene 
encompassing the region around the first exon and including the entire first intron 
and the second exon, as it can be seen on the UCSC genome browser 
(http://genome.ucsc.edu/). To locate potential cis-regulatory elements in this region 
we took advantage of the different bioinformatic tools implemented in the browser. 
Both PhyloP and PhastCons (24) tracks show 4 non-coding regions that are 
conserved among 46 vertebrate species, represented as positive peaks. The first 
peak (-319/+82) corresponds to exon 1 and upstream region; the other three peaks 
(+1500/+1900, +3100/+3450, +4700/+5200) are located in the intron between exon 
1 and 2. All of these four sequences have positive scores in the GERP track. 
Positive scores represent a substitution deficit (i.e. fewer substitutions than the 
average neutral site) and thus indicate that these sites are under evolutionary 
constraint. This evolutionary conservation suggests the possibility of regulatory 
functions. Further indications for regulatory potential come from areas of DNaseI 
hypersensitivity, an indication of accessible chromatin. The corresponding track 
shows, among others, a weak cluster (obtained from 2 experiments with H1-hESC) 
localized to the region of the transcription start and one very strong one (result from 
114 experiments with various cell lines) present at the +4700/+5200 conserved 
region. Finally, the last track on the bottom shows the repeating elements mapped 
to this region.  
In the present study, we focused on the conserved region immediately upstream of 
the transcription start site, assuming that this corresponds to the promoter of the 
gene, while the conserved regions inside the first intron may be distal regulatory 
elements. 
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Figure III.1 – A) Genomic localization of the human tenascin-W gene. The position of tenascin-W 
gene is indicated by a red line on the chromosome 1 ideogram. A schematic representation of the 
gene structure shows the distribution of tenascin-W 19 exons. Absolute chromosome coordinates 
are indicated above the scheme. B) UCSC browser display of the 5’ and upstream region of human 
tenascin-W gene. The uppermost track shows the gene structure, with coordinates relative to the 
transcription start. The second and third tracks show the basewise conservation among vertebrates 
as calculated by PhyloP (blue/red histogram) and PhastCons (green histogram). The fourth track 
displays the GERP score (grey histogram). Conserved regions are revealed by positive peaks in 
these histograms. The lower tracks represent with grey and black boxes DNaseI hypersentivity 
clusters and region of repetitive DNA, respectively. 
 
III.3.1.2 – Characterization of the human tenascin-W promoter 
In order to identify regulatory elements in the conserved region upstream of the 
TNW gene, a 501bp fragment of genomic DNA spanning a region of TNW that is 
423 bases 5’ and 78 bases 3’ of the start site of transcription, and thus includes the 
entire exon1, was inserted into a promoterless pSEAP2-basic vector to control the 
expression of the secreted embryonic alkaline phosphatase reporter. This reporter 
plasmid, pSEAP-TNW(-423), was cotransfected with a plasmid expressing a 
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secreted luciferase (pMetLuc-Control) 
to control for transfection efficiency 
into three osteosarcoma cell lines, 
U2OS, Saos-2, KRIB, and into one 
fibrosarcoma cell line, HT1080. None 
of these cell lines express detectable 
levels of endogenous tenascin-W 
protein in standard cell culture 
conditions. However, since tenascin-
W is known to be involved in bone 
development and is expressed in the 
periosteum in the adult, we decided to 
use these easily transfectable cell 
lines for our promoter study. The 
relative activity of the -423/+78 TNW 
region was compared between the cell 
lines by measuring the secreted 
alkaline phosphatase activity in the 
culture media, normalized to the level 
cells showed the highest reporter 
gene activation and were thus 
selected for further studies. To further 
characterize the TNW promoter, SEAP 
reporter plasmids containing up to 
1800bp and progressively shorter 
fragments 5’ of the TNW gene were 
transiently transfected in HT1080 cells 
(Fig.III.3A). No significant reduction in reporter activity was observed when the 
region spanning nucleotides -1800 to -319 was progressively deleted and the 
activity of the tested constructs remained 30-fold higher than the promoterless 
pSEAP2-basic background activity. By contrast, plasmids pSEAP-TNW(-252) and 
pSEAP-TNW(-148) displayed significantly lower reporter activity, 2.38 fold and 3.36 
fold lower than pSEAP-TNW(-319), respectively.  
Figure III.2 – Osteosarcoma (USO2, Saos-2 and 
KRIB) and fibrosarcoma (HT1080) cell lines were 
transiently transfected with a secreted alkaline 
phosphatase (SEAP) reporter under the control of 
the -423/+78 region of the TNW gene. Reporter 
activity in the culture medium was normalized 
against a co-transfected secreted luciferase 
expressing vector used to control for transfection 
efficiency. Error bars represent standard error of 
the means of a single experiment done in triplicate. 
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Thus, the TNW minimal promoter is most likely located within nucleotides -319 to 
+78. Interestingly, the very same nucleotides correspond to the highly evolutionary 
conserved nucleotides 5’ of TNW exon1 (cf. Fig.III.1). To further characterize this 
region, we made internal deletions within the pSEAP-TNW(-512) plasmid. All 
together, the eight deletion mutants cover the genomic region from -423 to +78 
(Fig.III.3A). No significant variation in reporter activity was observed when the 
plasmids carrying the deletions -423/-319, -59/-34, and +1/+78 (exon1) were 
transiently transfected in HT1080 cells. Deletion of nucleotides -79 to -59 resulted in 
a significant 2-fold reduction of reporter activity, suggesting the importance of these 
20bp for gene activation. 
However, the most striking results were observed when deletions -319/-252, -252/-
148, and -148/-79 were tested. All three of this deletion mutants showed a 
significant increase in reporter activity when compared to the original pSEAP-TNW(-
512) of 4.82-, 3.30-, and 4.37-fold, respectively. Similar results were observed when 
plasmids pSEAP-TNW(-512) and pSEAP-TNW(-512)∆-148/-79 were transfected in 
U2OS, Saos-2, and KRIB cells to confirming the inhibitory effect of this region on 
reporter activity in several cell lines (Fig.III.4). 
A hypothetical model to explain the results obtained is presented in Fig.III.3B. This 
model encompasses at least three regulatory factors/complexes that bind the 
Figure III.3 (previous page) – A) Fibrosarcoma cells HT1080 were transiently transfected with 
reporter constructs expressing SEAP under control of various deletion mutants of the genomic 
sequence upstream the TNW gene. Dotted lines represent nucleotides deleted in the construct. 
Co-transfected secreted luciferase vector was use as control for transfection efficiency and for the 
normalization. The figure represents a summary of multiple experiments in which different 
combination of constructs were transfected in triplicate. Results from different experiment were 
calibrated using the -512/+78 construct as reference, as it was transfected in every experiment. 
The number of experiments in which a construct was used it is indicated beside its bar in the 
graph. Error bars represents standard error of the mean. Asterisks indicate a p<0.001 in a Mann-
Whitney U test against the -512/+78 construct. B) A speculative model that explains the observed 
results. Three cis-regulatory elements, -512/-423, -319/-79, and -79/-59, are recognized by three 
putative transcription regulator complexes, identified by #2, #3 and #1 respectively. When the 
sequence is intact (on the left), regulatory complex #2 it is inhibited by complex #3: The 
transcription is mildly activated by complex #3 and #1; when part of the sequence from -319 to -79 
is absent (on the right; in this case -148/-79), complex #3 do not inhibit complex #2 anymore: The 
transcription is strongly activated by complex #2 and #1. C) The table summarizes the three-
complexes interpretation in case of all the relevant construct tested. For each plasmid, the putative 
complexes that can bind and the observed normalized SEAP activity are indicated. Complex #2 is 
indicated between brackets when it is repressed by complex #3. 
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identified cis-elements on the DNA 
sequence acting together in the 
regulation of the transcription of TNW 
(Fig.III.3C). Nucleotides -79 to -59 are 
recognized by complex #1, a weak 
transcriptional activator. Nucleotides -
512 to -423 are required for the 
binding of complex #2, a stronger 
activator of transcription, which in turn 
is inhibited by complex #3 requiring 
the complete sequence from 
nucleotide -319 to -79 to exert its 
inhibition on complex #2. On the 
intact construct pSEAP-TNW(-512) 
the three complex bind the promoter, 
#2 is inhibited by #3 and #3 and #1 
together weakly activate the 
transcription. The level of transcription 
is similar in constructs pSEAP-TNW(-
423) and pSEAP-TNW(-319) where 
only complex #3 and #1 can bind. In constructs pSEAP-TNW(-252) and pSEAP-
TNW(-148) only complex #1 binds and the level of transcription in reduced. Similar 
reduction is observed when complex #1 binding region is lost, in pSEAP-TNW(-
512)∆-79/-59, and the only activation is from #3, since #2 is inhibited by #3. Finally, 
in constructs pSEAP-TNW(-512)∆-319/-252, pSEAP-TNW(-512)∆-252/-148, and 
pSEAP-TNW(-512)∆-148/-79, the complex #2 is no longer repressed by #3 and the 
transcription level is strongly increased (Fig.III.3B,C).  
Although speculative and oversimplified, this interpretation of the data fits with the 
observations and the model of transcriptional repression as depicted here offers an 
explanation why TNW is not expressed in cultured cells.  
 
 
Figure III.4 – U2OS, Saos-2, KRIB and HT1080 
cells were transfected with SEAP reporter 
constructs under the control of the -512/+78 region 
of the TNW gene, intact (dark grey) or missing 
nucleotides from -148 to -79 (light grey). The graph 
shows the reporter activity in the medium, 
normalized against secreted luciferase activity. 
Error bars indicate standard error of the mean of a 
single experiment done in triplicate. 
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Figure III.5 – Predicted transcription factor binding sites in the evolutionary conserved region 
immediately upstream the tenascin-W gene. Conserved binding sites between human and dog 
(upper panel), between human and cow (middle panel) and between human and mouse (lower 
panel) are shown as obtained by running the rVISTA 2.0 algorithm. 
 
III.3.1.3 – In silico prediction of transcription factor binding sites 
An examination of the genomic sequence used for the reporter gene assays was 
conducted using MatInspector (www.genomatix.de), and several potential binding 
sites for transcription factors were found (data not shown). A similar search of 
binding sites for transcription factors that in addition considers the evolutionary 
conservation of the analyzed sequence was performed using rVISTA 2.0 (25), 
comparing the human genomic sequence with the orthologous sequences of dog, 
cow and mouse (Fig.III.5). Using this method, a smaller set of putative conserved 
binding sites were found; among them, the GATA binding site (5’-aaaaGATAatgag-
3’; on the minus strand) between nucleotides -137/-125 caught our interest. Recent 
work reported GATA-6 as a transcriptional repressor of tenascin-C in fibroblasts 
(26).  
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Fig III.6 – A) HT1080 cells were transfected with reporter constructs expressing SEAP under the 
control of the -512/+78 region of the TNW gene, intact or missing the indicated nucleotides. The 
graph shows the reporter activity in the medium, normalized against secreted luciferase activity. 
Error bars indicate standard error of the mean of two experiments done in triplicate. B) HT1080 cells 
were transfected with SEAP reporter under control of region -512/+78 intact, with nucleotides -148/-
79 deleted, or with a 4-nucleotides mutation in the putative GATA binding (the mutation is indicated 
by an “M”); region -252/+78, intact or with the GATA site mutation; region -148/+78, intact or with the 
GATA site mutation. The graph shows the reporter activity in the medium, normalized against 
secreted luciferase activity. Error bars indicate standard error of the mean of a single experiment 
done in triplicate. 
 
Furthermore, the conserved GATA site is located in one of the regions that increase 
the reporter gene expression upon deletion and according to our model is binding a 
repressor complex. Interestingly, the GATA binding site is not conserved in mouse. 
To evaluate the importance of this GATA site the promoter region corresponding to 
nucleotides -148 to -79 was divided in four sub regions, -148/-137, -137/-123, -123/-
101, and -101/-79, and four new SEAP plasmids based on pSEAP-TNW(-512) 
carrying each deletion were transfected in HT1080 cells  (Fig.III.6A). Interestingly, 
pSEAP-TNW(-512)∆-137/-123, the construct in which the deletion overlaps with the 
conserved putative GATA binding site, displayed the highest reporter activity. To 
confirm the importance of the GATA binding site with an alternative approach, we 
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mutated the four nucleotides of the core of the binding site (-131/-128) from TATC to 
CTCG in three constructs of different lengths. When transfected in HT1080 cells 
(Fig.III.6B), we observed that in pSEAP-TNW(-512) the mutation induced the 
reporter gene expression at a level comparable with the full -148/-79 deletion. Also 
in pSEAP-TNW(-252 and pSEAP-TNW(-148), the mutation increases the reporter 
activity. Thus, the GATA-binding region is an important element for the observed 
transcriptional repression of the TNW constructs. Although the regulatory 
mechanism may be more complicated than the one postulated, taken together, 
these last experiments suggest that a complex that acts as transcriptional repressor 
requires the intact -131/-128 sequence to exert its effect. 
 
III.3.1.4 – DNA pull-down of complexes binding to the repressor region 
We decided to use a proteomic approach to identify the protein complexes that bind 
the identified repressive element in the tenascin-W promoter. Biotinylated double 
strand DNA probes corresponding to nucleotides -149 to -119, either wild-type (WT) 
or containing the -131/-128 mutation (MUT), were incubated with nuclear extract of 
Figure III.7 – Schematic of the pull-down assay. Wild-type (WT) and mutated (MUT) -149/-119 
double strand DNA probes were incubated with nuclear extracts from HT1080 cells, in presence of 
an excess of unlabeled MUT or WT probe respectively (the red star represents the -131/-128 
mutation). A control without probe was also included in the experiment. The mixtures were coupled 
to streptavidin-conjugated paramagnetic beads and subjected to extensive washing. The 
nucleoprotein complexes were eluted with an excess of unlabeled probe and subjected to MS 
analysis. 
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HT1080 cells. To increase the specificity of binding, an excess of unbiotinylated 
MUT probe was added to the nuclear extract incubated with the biotinylated WT 
probe; similarly, an excess of unbiotinylated WT probe was included in the MUT 
sample. The resulting nucleoprotein complexes were pulled down using 
streptavidin-conjugated paramagnetic particles and washed extensively. To 
estimate the background noise due to unspecific binding to the beads, a negative 
control in which paramagnetic particles were incubated with nuclear extract in 
absence of any probe was included in the experiment. Specific elution was 
performed by incubation with an excess of the appropriate unlabeled probe (for the 
negative control an equimolar mixture of WT and MUT unlabeled probe was used). 
Eluted proteins were then identified by mass spectrometry (MS). A schematic 
summary of the whole procedure is depicted in Fig.III.7. The output of the MS 
analysis consisted in a list of identified proteins and their average normalized 
abundance in each sample (WT, MUT and CTR). The list was first examined 
according to the GO terms associated with each entry: cytosolic, mitochondrial, and 
transmembrane proteins were purged from the list, as obvious contaminants of the 
nuclear extract. Ratios between the average normalized abundance in eluates of 
WT, MUT and CTR were calculated for each protein in the list. Only proteins that 
were at least twice as abundant in WT or in MUT in comparison with CTR were kept 
in the list. This operation aimed at filtering out most of the noise due to unspecific 
binding to the paramagnetic particles. Since our aim was to identify proteins that are 
part of the postulated repressor complex that recognizes the original -131/-128 
sequence, we were interested in proteins that are more abundant in the WT sample 
than in the MUT one. We therefore calculated the ratio between the average 
normalized abundance in WT and in MUT eluates for each protein, and assembled 
a list of proteins with a ratio higher than 1. The filtered list of results from one typical 
experiment containing 61 proteins is presented in Table III.1, ranked according the 
WT/MUT ratio.  
Although at least GATA-2, GATA-3, GATA-4 and GATA-6 transcripts are present in 
HT1080, as assessed by RT-PCR (data not shown), the pull down experiment gave 
no indication of an interaction of any member of the GATA family with the conserved 
GATA binding site present in the WT probe. Interestingly though, two proteins that 
contain a GATA-type zinc finger domain, GATAD2B and GATAD2A, are in the list, 
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in position #37 and #49 respectively. Also known as transcriptional repressor P66β 
and -α, these proteins can interact with each other and are often part of the Mi-
2/NuRD complex (27). Two other members of Mi-2/NuRD are also found in the list: 
the core member of the complex, CHD4, in position #8, and RBBP4, in position #45. 
The Mi-2/NuRD is a well studied transcriptional repressor complex, which acts 
through chromatin remodeling and histone modifications: it represents a promising 
candidate for the role of a repressor of TNW gene transcription.  
Another protein in the list, SUZ12 (position #50) is also linked to transcriptional 
repression as an essential component of the Polycomb repressive complex 2 
(PRC2). Although SUZ12 relative abundance is low and the protein is only slightly 
more abundant in WT sample than in MUT, it might be worthy of further 
investigation. 
 
III.3.1.5 – Chromatin immunoprecipitation  
To further strengthen the hypothesis that Mi2/NuRD and PRC2 complexes bind the 
endogenous human tenascin-W promoter in vivo, we performed chromatin 
immunoprecipitation (ChIP) assay. The chromatin extracted from HT1080 cells was 
immunoprecipitated using antibody against CHD4, against SUZ12, or non targeting 
IgG, and the enrichment of tenascin-W promoter (position -428 to -215) was 
analyzed by quantitative real-time PCR (Fig.III.8). Two genomic regions were used 
as negative controls for CHD4 and SUZ12 binding, a long interspersed nuclear 
element (LINE) located 1800 bp upstream the transcription start site, and tenascin-
W exons 10 and 11 and the non conserved intron in between. We observed 
enrichment relative to the input of the promoter region three times higher when the 
anti-CHD4 antibody is used compared to non-targeting IgG. By contrast, the two 
control region display a negligible enrichment. Our results, therefore suggest that 
indeed the Mi2/NuRD complex occupy the promoter of human tenascin-W.  
In case of SUZ12, although enrichment was observed on the promoter region, the 
two control regions resulted enriched as well, suggesting that the binding of PRC2 
may be not specific to tenascin-W promoter. 
RESULTS - UNPUBLISHED 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.8 – ChIP assay. HT1080 
chromatin was extracted, 
immunoprecipitated with anti CHD4, anti 
SUZ12 antibody, and non specific IgG. 
Primers designed on tenascin-W 
promoter (TNW-428/-215), on a 
repetitive DNA sequence upstream 
tenascin-W gene (LINE), or on the 
sequence between exon 10 and 11 
(Ex10-11) were used for quantitative 
real-time PCR analysis. Results are 
plotted relative to input DNA. Error bars 
indicate standard error of the mean of 
two independent experiments. 
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Rank 
# 
Gene 
name Protein names 
Average Normalized 
Abundances WT/MUT 
(>1) 
MIN 
diff 
CTR 
(>2) WT MUT ctr 
1 PHF6 PHD finger protein 6  19400 2293.03 10.64 8.46 215.51 
2 EXOSC7 Exosome complex exonuclease RRP42  7942.48 1943.52 368.33 4.09 5.28 
3 SMARCE1 
SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin 
subfamily E member 1  
118000 50000 16700 2.36 2.99 
4 PARP1 Poly [ADP-ribose] polymerase 1  1370000 589000 251000 2.33 2.35 
5 PDCD11 Protein RRP5 homolog  33600 16400 4174.6 2.05 3.93 
6 UHRF1 E3 ubiquitin-protein ligase UHRF1  64700 32200 12600 2.01 2.56 
7 EXOSC1 3'-5' exoribonuclease CSL4 homolog  22100 11000 1125.7 2.01 9.77 
8 CHD4 Chromodomain-helicase-DNA-binding protein 4  6513.1 3399.19 95.71 1.92 35.52 
9 HMGN1 Non-histone chromosomal protein HMG-14  10400 5753.01 2853.7 1.81 2.02 
10 FAU 40S ribosomal protein S30 35400 19700 6743.3 1.8 2.92 
11 RPL22 60S ribosomal protein L22  52000 29100 14100 1.79 2.06 
12 MAP4 Microtubule-associated protein 4  39300 22000 8328.2 1.79 2.64 
13 THOC4 THO complex subunit 4  1360000 762000 280000 1.78 2.72 
14 MYBBP1A Myb-binding protein 1A 13900 7840.2 3375.5 1.77 2.32 
15 C12orf43 Uncharacterized protein  3023.93 1730.42 163.69 1.75 10.57 
16 RPS25 40S ribosomal protein S25 63500 38200 13200 1.66 2.89 
17 KIFC1 Kinesin-like protein KIFC1  1570.7 958.92 59.3 1.64 16.17 
18 ATF1 Cyclic AMP-dependent transcription factor ATF-1  907.02 561.26 73.14 1.62 7.67 
19 SNRPD1 Small nuclear ribonucleoprotein Sm D1  43500 27400 9690.5 1.59 2.83 
20 TPX2 Targeting protein for Xklp2  9457.58 6014.92 488.02 1.57 12.33 
21 HMGA1 High mobility group protein HMG-I/HMG-Y  12000 7908.54 2553.3 1.52 3.1 
22 EIF2S1 Eukaryotic translation initiation factor 2 subunit 1  6958.14 4692.83 307.89 1.48 15.24 
23 KPNA3 Importin subunit alpha-3  889.05 602.24 169.62 1.48 3.55 
24 HNRNPU Heterogeneous nuclear ribonucleoprotein U  2900000 1990000 388000 1.46 5.13 
25 RPS7 40S ribosomal protein S7 455000 314000 43800 1.45 7.17 
26 EXOSC10 Exosome component 10  241000 169000 63500 1.43 2.66 
27 SNRPF Small nuclear ribonucleoprotein F  1008.8 721.99 9.74 1.4 74.13 
28 FMR1 Fragile X mental retardation 1 protein  7228.75 5190.93 1782.6 1.39 2.91 
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29 EXOSC4 Exosome complex exonuclease RRP41  1858.33 1336.77 149.58 1.39 8.94 
30 LYAR Cell growth-regulating nucleolar protein 4628.72 3331.49 947.39 1.39 3.52 
31 DDX56 Probable ATP-dependent RNA helicase DDX56  2948.08 2152.85 188.32 1.37 11.43 
32 PRKDC DNA-dependent protein kinase catalytic subunit  11400 8853.29 4309 1.29 2.05 
33 TMPO Lamina-associated polypeptide 2, isoform alpha  50800 39500 14600 1.29 2.71 
34 SART1 U4/U6.U5 tri-snRNP-associated protein 1  9946.74 7741.77 792.15 1.28 9.77 
35 DDX47 Probable ATP-dependent RNA helicase DDX47  14900 11700 890.73 1.27 13.14 
36 RBM27 RNA-binding protein 27  31000 24400 2206.2 1.27 11.06 
37 GATAD2B 
Transcriptional repressor p66-
beta (GATA zinc finger 
domain-containing protein 2B)  
3771.25 2970.59 910.29 1.27 3.26 
38 RPL23 60S ribosomal protein L23 226000 180000 78900 1.26 2.28 
39 WDR5 WD repeat-containing protein 5  1748.16 1393.19 566.61 1.25 2.46 
40 PRPF19 Pre-mRNA-processing factor 19  280000 224000 109000 1.25 2.06 
41 NOLC1 Nucleolar and coiled-body phosphoprotein 1  166000 133000 48800 1.25 2.73 
42 RSL1D1 Ribosomal L1 domain-containing protein 1  115000 92500 40200 1.24 2.3 
43 RPS2 40S ribosomal protein S2 24800 20000 2000.4 1.24 10 
44 HMGN4 
High mobility group nucleosome-
binding domain-containing 
protein 4 
11500 9374.38 4638.1 1.23 2.02 
45 RBBP4 Histone-binding protein RBBP4  29500 24200 10200 1.22 2.37 
46 POLDIP3 Polymerase delta-interacting protein 3 135000 111000 19600 1.22 5.66 
47 SMARCA2 Probable global transcription activator SNF2L2 1615.87 1339.49 364.21 1.21 3.68 
48 RBM14 RNA-binding protein 14 99000 83500 20200 1.19 4.13 
49 GATAD2A 
Transcriptional repressor p66-
alpha (GATA zinc finger 
domain-containing protein 2A) 
4134.73 3518.76 276.88 1.18 12.71 
50 SUZ12 
Polycomb protein SUZ12 
(Chromatin precipitated E2F 
target 9 protein) 
550.09 469.5 190.44 1.17 2.47 
51 RPS16 40S ribosomal protein S16 39200 34300 1572.8 1.14 21.81 
52 HNRNPR Heterogeneous nuclear ribonucleoprotein R 465000 408000 152000 1.14 2.68 
53 HIST1H2BC Histone H2B type 1-C/E/F/G/I 157000 139000 43500 1.13 3.2 
54 RPS27L 40S ribosomal protein S27-like 873.1 777.51 86.63 1.12 8.98 
55 RPL35 60S ribosomal protein L35 10900 9773.8 927.35 1.12 10.54 
56 PSIP1 PC4 and SFRS1-interacting protein  6109.45 5488.09 1434.2 1.11 3.83 
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57 POLR2E DNA-directed RNA polymerases I, II, and III subunit RPABC1 823.99 760.95 159.1 1.08 4.78 
58 EXOSC3 Exosome complex exonuclease RRP40 34400 31800 12000 1.08 2.65 
59 ACIN1 
Apoptotic chromatin 
condensation inducer in the 
nucleus 
11900 11300 563.1 1.05 20.07 
60 NOM1 Nucleolar MIF4G domain-containing protein 1 820.23 786.45 144.38 1.04 5.45 
61 TOP1 DNA topoisomerase 1 196000 188000 78900 1.04 2.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III.1 – List of the proteins identified by MS on the eluates of the DNA pulldown experiment. The 
average normalized abundance of each protein in the three conditions (WT, MUT and ctr) is 
indicated. The proteins are ranked according WT/MUT ratio. Proteins of potential interest are in bold 
font. 
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III.3.2 – Bone marrow-derived stem cells differentiated to 
osteoblasts express tenascin-W in vitro 
In collaboration with Arnaud Scherberich, Department of Biomedicine, University 
Hospital Basel, Basel, Switzerland 
 
While tenascin-W can be induced by BMP-2 stimulation in a variety of murine cells 
(i.e. C2C12 (28), MEF(29), HC11 (29)), we were not able to detect tenascin-W 
expression in any human cell line tested so far, kept in standard culture condition, 
stimulated or not with a panel of growing factors (i.e. FGF2, BMP2, TNFα)  (data not 
shown). 
Since tenascin-W is prominently expressed during embryonic bone development 
(30) we decided to test its expression in a in vitro model of endochondral bone 
formation (31). The model consists in a 3D culture of bone marrow-derived, adult 
mesenchymal stem cells (BMSC) kept first in chondrogenic medium (with TGFβ1) 
for 3 weeks, followed by 2 weeks in hypertrophic medium (without TGFβ1 and with 
beta-glycerophosphate and thyroxin). Under these conditions, the BMSC undergo 
differentiation and display clear cartilaginous features at the core of the structure 
surrounded by a mineralized rim. In order to look for tenascin-W expression, 
cryosections obtained from the above described 3D cultures were stained with anti-
tenascin-W monoclonal antibodies (Fig.III.9A). The result showed a strong positive 
signal in the mineralized periphery of the culture. The staining is strongly reduced 
when the primary antibody is pre-incubated with purified tenascin-W, confirming the 
specificity of the observed signal (data not shown). 
We decided to test if BMSC undergoing osteogenic differentiation express tenascin-
W also in standard 2D cultures. At that purpose, we cultured BMSC derived from 
three different patients either in osteogenic medium (containing dexamethasone, 
beta-glycerophosphate and ascorbic acid-2-P) or in control medium (growth 
medium). After three days in osteogenic medium, cells start to express the 
osteoblasts marker alkaline phosphatase (ALP), and the expression reaches the 
maximum at the end of the first week (Fig.III.9B). As expected, cells in control 
medium remain undifferentiated and do not express ALP. The expression of 
tenascin-W follows a similar kinetic, increasing during the first week of culture in 
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osteogenic medium and remaining low in control cells (Fig.III.9C). The expression of 
tenascin-W was confirmed at protein level by immunofluorescence staining of cells 
kept in osteogenic medium for one week, using anti-tenascin-W antibody (Fig.III.9D, 
lower panels). Tenascin-W appears as a mesh of extracellular fibers that surrounds 
the differentiated cells, and is completely absent in the cells cultured in control 
medium. Similar results were obtained with BMSC derived from the other two 
patients. In our knowledge, this is the first report of human cells that express 
endogenous tenascin-W in culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.9 (next page) – Bone marrow-derived stem cells (BMSCs) differentiated to osteoblasts 
express tenascin-W. A) BMSC were cultured as 3D pellet for three weeks in chondrogenic medium, 
followed by two weeks in hypertrophic medium. The disc-shaped pellets were harvested, frozen and 
9 µm tick cryosections were prepared. The picture shows the immunostaining of a section using anti-
tenascin-W monoclonal antibody. The specific tenascin-W signal is localized in correspondence of 
the mineralized border. Scale bar = 200 µm. B) In BMSC cultured in osteogenic medium the 
expression of the marker for osteogenic differentiation alkaline phosphatase (AP) increases after 3 
days, while in cells maintained in growth medium its level remains low. Results of a typical 
experiment are shown. C) Expression of tenascin-W mRNA steadily increases during the first days of 
osteogenic differentiation of BMSCs, reaching the peak after one week. In control cells, tenascin-W 
level remains negligible. Error bars represent standard error of the mean of two experiments. D) 
BMSCs cultured for one week in osteogenic medium or growth medium were stained for AP to 
demonstrate osteogenic differentiation (upper pictures), or immunostained with anti-tenascin-W 
monoclonal antibody and a secondary antibody conjugated with Alexa-488 (lower pictures). Only 
differentiated cells display specific tenascin-W staining (scale bars=200 µm).       
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IV. DISCUSSION 
IV.1 – Tenascin-W in the context of tumors 
Since its discovery as antigen present in glioma-associated stroma (32), tenascin-C 
has been found to be strongly expressed in the extracellular matrix of various types 
of cancer (17, 33). Due to the structural analogy and the partially overlapping 
pattern of expression with tenascin-C, it was natural to study the expression and the 
functions of tenascin-W in the tumor context. The first observation of tenascin-W in 
the tumor stroma was made in  mouse models for mammary carcinogenesis, where 
its presence around primary tumors was linked with the likelihood to develop 
metastasis (29). The association with tumor stroma was confirmed in human by a 
study that found tenascin-W expression in the large majority of breast cancer 
lysates subjected to immunoblotting (34). Immunohistochemistry showed that 
tenascin-W staining was localized in the stromal compartment that surrounds the 
transformed epithelial cells. In contrast, tenascin-C was in some cases observed to 
be expressed by the tumor cells themselves. Notably, neither tenascin-W nor 
tenascin-C was detected in the healthy breast tissue. A following study extended the 
observations to colorectal cancer (35). Also in this case, tenascin-W was detected in 
the majority of the samples examined, localized in the stroma around the tumors. 
Interestingly, whereas the healthy colon tissue is devoid of tenascin-W, strong 
staining was observed for tenascin-C in the normal colon mucosa. 
 
Here, we have presented new studies that investigated tenascin-W in brain tumors 
(see III.1.1) and in melanomas, pancreas, kidney and lung carcinomas (see III.2.1). 
We were not able to detect tenascin-W expression in any of the corresponding 
normal tissues, with the exception of a relatively low amount in kidney. This is the 
most remarkable difference with tenascin-C, since we detected the latter in every 
normal organ examined, except for breast and heart tissue. Considering that 
tenascin-C overexpression has been associated with other pathological conditions 
than cancer, namely inflammation, infection, asthma, fibrosis and wound healing 
(17, 33), tenascin-W seems to be a more specific marker for cancer. However, since 
tenascin-C is expressed in numerous splice variants, there remains the possibility 
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that certain isoforms could be more tumor-specific than others and provide a good 
target as well (36, 37). For instance in normal kidney, pancreas and colon samples, 
we observed only a low molecular weight tenascin-C isoform, while in tumors a 
number of larger variants are visible in the immunoblots. 
 
Our observations on glioblastoma samples revealed an obvious coincidence 
between tenascin-W staining and the tumor microvasculature. Double 
immunofluorescence staining together with the blood vessel marker von Willebrand 
factor confirmed the colocalization of tenascin-W and endothelial cells. Prompted by 
this finding, we looked for the same pattern of expression in other types of solid 
tumors. By using the same double immunofluorescence approach, this time using 
CD31 as endothelial cell marker, we confirmed tenascin-W association with blood 
vessels also in the case of lung and kidney carcinomas. Additional observations (not 
shown) on a limited number of ovarian and prostate cancer samples gave similar 
results. In breast tumors, tenascin-W overexpression is in general higher and not 
limited to the close proximity of blood vessels, but distributed in the whole stromal 
compartment, making the colocalization less obvious. In general, we can conclude 
that the presence of the protein around tumor blood vessels seems to be a common 
feature for tenascin-W-expressing tumors.  
We demonstrated that tenascin-W has a pro-migratory effect on endothelial cells. As 
assessed by our in vitro experiments using HUVEC, cell motility increased in 
presence of tenascin-W. Additionally, HUVEC spheroids embedded in a collagen-
type I gel sprouted when tenascin-W was present in the surrounding matrix. Since 
proangiogenic activities have also been described for tenascin-C in several studies 
(38, 39), our results suggested a common proangiogenic role for tenascin-C and 
tenascin-W. A very recent study compared tumor angiogenesis with physiological 
angiogenesis using a proteomic approach (40). By comparing the protein 
expression profile of proliferating vessels in glioblastoma with the one of those in 
endometrium, a tissues in which physiological angiogenesis takes place, the authors 
identified tenascin-C among the protein aberrantly expressed only in tumor blood 
vessel. In contrast with our results, said study did not report tenascin-W among the 
tumor blood vessel-specific proteins. An explanation for this discrepancy may be 
that unlike us, the authors of the mentioned study did not specifically look for 
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tenascin-W and tenascin-W, although there, did not pass the strict filtering process 
applied on the mass spec data or was not expressed at high enough levels to be 
detected by their method. 
 
The amount of tenascin-W and tenascin-C varies significantly among tumor 
samples, in all divers solid tumors examined. Therefore, we searched for 
correlations between tenascin-W overexpression and    clinicopathological features 
of the tumors. A previous study (41) reported that the mean level of tenascin-W in 
low-grade breast tumors (G1/G2) is significantly higher than in high-grade tumors 
(G3), although the values within each group are so spread that there are high-grade 
samples with high level of tenascin-W and vice versa. 
By contrast, the study conducted on lung tumor patients presented here suggests a 
direct correlation between tenascin-W level and the grade of the tumor; high-grade 
tumors (G3/G4) have a statistically significant higher mean level of tenascin-W 
compared to normal lung tissue, and there seems to be a tendency for tenascin-W 
to increase with tumor grade (Supplementary figure V.2.1). In the same set of 
samples, tenascin-C levels appear consistently elevated regardless of the tumor 
grade and are not significantly higher than in the normal lung tissue of the same 
patient. Although we are aware that the number of samples examined is too small to 
draw definitive conclusions, there seems to be a tendency for increased tenascin-W 
expression in higher grade lung tumors. 
 
Many studies over the years revealed the utility of tenascin-C as biomarker for many 
aggressive cancers, with predictive value for local recurrences and metastatic 
dissemination (42–44). Moreover, tenascin-C has been a target of different anti-
cancer therapies, including the delivery of cytokines or radionuclides to the tumor 
using tenascin-C-specific monoclonal antibodies (45–47) or aptamers (48, 49). We 
think that in the future tenascin-W might have the better potential to serve as tumor 
biomarker, due to its cancer-specific expression, its proximity to blood vessels that 
suggests accessibility from the blood stream, and finally its positive influence on 
tumor angiogenesis that could be disrupted by such treatments. 
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IV.2 – Regulation of tenascin-W 
Our observations in immunohistochemical stainings of tumor sections presented 
here and previous immunoblot studies (34, 35) revealed that tenascin-W and 
tenascin-C relative ratios differ greatly from sample to sample. This implies the 
existence of independent regulatory mechanisms specific for each tenascin, but at 
the same time it does not exclude that the two genes also share conserved 
mechanism of regulation. 
Several publications are available on the structure of the tenascin-C promoter and 
its cis-regulatory elements (26, 50–54). By contrast, nothing has been published to 
date about the promoter of tenascin-W. To our knowledge, the results presented in 
section III.3.1 of this thesis represent the first experiments to characterize the 
promoter of the human tenascin-W gene. It is our ambition that through the study of 
the tenascin-W promoter and the identification of its regulatory elements, it might be 
possible to link the expression of the gene to particular transcription factors and 
specific signaling pathways. The outcome of such studies might clarify how the strict 
spatio-temporal regulation of tenascin-W expression is achieved during 
development and will possibly give an indication of why the gene is so prominently 
expressed in cancer. 
Very little is known about the regulation of tenascin-W. It has been reported 
previously that TNFα and BMP2 can induce tenascin-W expression in cultured 
murine cells, such as MEFs, C2C12 and 4T1 cells (28, 29). This seems to be 
different in human cells. Indeed, we were not able to detect endogenous tenascin-W 
expression in any of the numerous cell lines of human origin tested and neither 
TNFα nor BMP2 or any other growth factors tested induced tenascin-W expression 
in the human cells.  We therefore concluded that certain regulatory mechanism must 
be very different between the two species, and caution is advised before extending 
what has been learned in mouse to human. Based on this, two main approaches to 
the study of tenascin-W regulation by reporter gene assay seemed reasonable: (i) 
adopting murine cell line models in which tenascin-W can be induced, in order to 
identify the mechanism of induction and the pathways involved, or (ii) making use of 
cell lines of human origin, to identify the mechanisms responsible for gene 
repression. We chose the latter option, since the results may be of broader interest. 
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We first examined the homo sapiens genomic region that contains the tenascin-W 
gene, looking for conserved non coding regions that may harbor regulatory 
elements (55). We found four regions highly conserved among vertebrates: three 
situated in the first intron and one immediately upstream of the putative untranslated 
tenascin-W first exon. The regions of high conservation located in the first intron 
may represent regulatory elements which often can be found in the first introns of 
genes (56). They are also compatible with the presence of an alternative promoter. 
Since the ATG codon is located in the second exon, this hypothetical transcript 
would result in the same protein, the only difference being in the 5’ UTR sequence 
and in the regulatory mechanism, which could be tissue-specific. After performing 
5’RACE on RNA extracted from few human cell lines (data not shown), and 
examining human EST collections, we have no evidence of any alternative tenascin-
W transcript, but its existence could not be ruled out yet and further investigations 
are needed. 
The study presented here focuses on the conserved region immediately upstream of 
the first untranslated exon, assuming that it corresponds to the promoter of the main 
tenascin-W transcript. The promoter activity was confirmed using SEAP reporter 
assays. Progressively shortened constructs were transfected into human 
fibrosarcoma cells (HT1080) resulting in a drop in reporter gene activity when the 
sequence was shorter than 319 bp upstream of the putative transcription starting 
site (TSS). Interestingly, 320 bp is precisely the length of the conserved region 
upstream the first exon. 
Adopting an approach of using internal deletion constructs, we were surprised to 
observe significant increases in reporter activity when constructs with deletions 
encompassing nucleotide -319 to -79 were transfected. An obvious explanation is 
that the deleted sequence harbors a cis-regulatory element involved in gene 
repression. A more detailed interpretation is presented in section III.3.1.2 (Fig. 
III.3B), where a speculative model that takes in accounts of all the observations is 
illustrated.  
Further examination of the -319/-79 region with a software that predicts putative 
binding sites for transcription factors revealed a conserved GATA binding site 
located between nucleotides -137 and -125. Considering that a recent report 
identified GATA-6 as a novel repressor of the tenascin-C gene (26), we investigated 
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the region that contains the GATA binding site in more detail. The importance of the 
putative GATA binding site was further supported by transfection of constructs in 
which the binding site was specifically inactivated, either by a short 13bp deletion or 
by a 4bp mutation, resulting in both cases in increased reporter activity. The same 
result was observed in three different osteosarcoma cell lines in which the 
experiment was repeated. Taken together, our experiments suggest that a repressor 
complex acts on the tenascin-W promoter, and the putative GATA site is involved in 
its recruitment to the promoter. 
In an effort to identify the repressor complex, we used a probe designed to match 
the sequence containing the GATA site in a DNA-pulldown assay in order to isolate 
proteins from nuclear extracts that specifically bind to this sequence. While a similar 
approach is commonly used to confirm the binding of a known protein to DNA, by 
following the pull down by western blot (for an example see (57)), DNA-pulldown 
followed by mass spectrometry identification of unknown binding complexes is far 
less common (58). In our protocol, two types of probes were employed, one 
corresponding to the native sequence and the other one carrying a mutated GATA 
site. The list of proteins enriched in the eluate corresponding to the wild type probe 
contained several interesting proteins. 
The protein that displayed the greatest specificity for the wild type sequence is PHD 
finger protein 6 (PHF6). It was more than 8-fold enriched using the wild type probe 
versus the mutated one. PHF6 is a protein that has been linked to Börjeson-
Forssman-Lehmann syndrome (59), a form of X-linked mental retardation, and to 
acute myeloid leukemia (60). It contains two PHD finger motifs and has probably a 
role in transcriptional regulation. PHD finger motifs recognize trimethylated histone 3 
on lysine 4 (61), thus it is not clear why PHF6 would bind to our oligo and  why the 
4-nucleotide mutation would affect its recruitment. 
The most abundant protein retrieved in the eluates was THO complex subunit 4 
(THOC4).  It was 1.8-fold enriched in wild type probe eluates versus the one with 
the mutated probe. THOC4 is a molecular chaperone, thought to regulate 
dimerization, DNA binding, and transcriptional activity of basic region-leucine zipper 
proteins (62).  
The most interesting finding however was the presence of four members of the 
nucleosome remodeling and histone deacetylase (NuRD, aka Mi-2) complex (27, 
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63, 64). The NuRD complex regulates gene expression through chromatin 
remodeling and is a well studied transcriptional repressor. Among the core 
components of the NuRD complex, our pulldown experiment identified the 
enzymatic subunit chromodomain-helicase-DNA-binding protein 4 (CHD4, aka 
Mi2β), the structural component retinoblastoma-binding protein 4 (RBBP4, aka 
RBAP48), and the two GATA zinc finger domain-containing proteins GATAD2A (aka 
P66α) and GATAD2B (aka P66β). The last two proteins contain a DNA-binding zinc 
finger domain very similar to the one shared by the GATA family of transcription 
factors. It is not implausible to think that the previously identified conserved GATA 
binding site in the promoter sequence is recognized by one or both of the proteins 
and that, in turn, GATAD2A and/or GATAD2B recruit the rest of the repression 
complex by protein/protein interactions (65). 
Another protein found, although in low quantity, in the pulldown eluted fractions was 
the polycomb protein SUZ12, part of the polycomb repressor complex 2 (PCR2) 
(66). None of the other components of this complex were found in our experiments, 
but at least in ES cells it has been reported that NuRD and PCR2 can act together 
at specific loci (67). Further experiments are necessary to confirm the specific 
binding before drawing any conclusion. 
We tested if NuRD complex and PCR2 complex associate to the human tenascin-W 
promoter also in vivo, through chromatin immunoprecitation with antibody against 
CHD4 and SUZ12, respectively. Our preliminary results indicate that indeed NuRD 
complex is recruited to tenascin-W promoter. In contrast, we could not see an 
enrichment of the tenascin-W promoter in the SUZ12 enriched precipitate speaking 
against an association of the PCR2 complex with the tenascin-W promoter in vivo. 
From our experiments a picture emerges suggesting that tenascin-W gene is kept 
silenced in cultured cells by the presence of the NuRD complex on its promoter due 
to recognition of the nucleotides -131/-128 by GATAD2A or GATAD2B, and 
subsequent remodeling of the chromatin in a packed, non accessible form for 
transcription. 
It would be interesting to test the association of the NuRD complex and tenascin-W 
promoter in murine cells. The GATA site we deem responsible for NuRD complex 
recruitment is not conserved in the murine sequence. For this reason, if our 
hypothesis is correct, the NuRD complex is not expected to associate with the 
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mouse tenascin-W promoter which remains accessible for transcription. This may 
explain why BMP-2 and TNFα can induce tenascin-W expression only in mouse 
cells and not in cells of human origin. 
 
IV.3 – Tenascin-W and bone marrow-derived mesenchymal stem 
cells 
The main site of tenascin-W expression is the extracellular matrix of developing 
bones (28, 68, 69). Various pre-osteoblastic cell lines can be differentiated to 
osteoblasts by BMP-2 stimulation (70). Additionally, BMP-2 can stimulate tenascin-
W expression in various murine cell lines (28, 29).  We presented here results that 
show that human mesenchymal stem cells induced to differentiate to osteoblasts by 
culture in standard osteogenic medium express endogenous tenascin-W (Figure III-
9). Remarkably, this is the first observation of tenascin-W being expressed by 
cultured human cells.  
To our knowledge, there are only two previous studies that measured tenascin-W 
transcript levels throughout osteogenic differentiation, both conducted on murine 
osteoprogenitor cell lines, and with contradictory results. Mikura et al., monitoring 
tenascin-W level in Kusa-A1 cells cultured in osteogenic medium for six days, 
observed a steady increase of tenascin-W transcript starting as soon as the 
differentiation was initiated (71). In the second and more recent study, Morgan et al. 
followed tenascin-W level in MC3T3-E1 cells during three weeks of osteogenic 
culture and reported a marked reduction in the expression with differentiation, that 
was reduced to one half during the first week (72). Our results from human MSC 
cultured in osteogenic medium for twelve days were consistent with Mikura’s 
observations of a significant increase in tenascin-W expression, with differentiation 
and are at least in partial contrast with Morgan’s observations, since we didn’t follow 
tenascin-W in the subsequent weeks. Morgan et al. commented on Mikura et al. that 
the opposite results are due to the less mature nature of Kusa-A1 cells compared to 
MC3T3-E1 cells, claiming that their cell model is more representative of the in vivo 
process. Although for the reasons previously exposed, one has to be careful to 
compared results obtained in human with ones obtained in mouse when speaking 
about tenascin-W, our models, the 3D culture model of endochondral bone 
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formation and the MSC-derived osteoblasts, show how tenascin-W is expressed in 
correlation with early mineralization. 
 
Mesenchymal stem cells have the potential to differentiate in a variety of cells like 
osteoblasts, chondrocytes, adipocytes, fibroblasts and muscle cells (73). We 
showed that MSC cultured in osteogenic medium start expressing tenascin-W, 
indicating that these cells have the ability to release the repression that keeps the 
gene silenced. What about tenascin-W expression when MSC are differentiated in 
other directions? When we cultured the MSC in adipogenic medium we did not 
detect any tenascin-W expression in the derived adipocytes (data not shown). Thus, 
this in vitro model resembles the tenascin-W expression in vivo, which was 
restricted to differentiating bone. 
The major source of MSC is bone marrow; MSC are traveling in the blood stream 
and are able to home at sites of inflammation and tissue repair (74). It has recently 
been shown that MSC are normally also recruited to tumor sites (75, 76), where 
they differentiate to tumor-associated fibroblasts and become part of the tumor 
microenvironment (15).  
We previously reported our observation of tenascin-W to be localized in the 
proximity of blood vessels in a variety of solid tumors. We want to propose here a 
speculation to explain this. MSC may be attracted from tumors by chemokines and 
factors secreted by tumor cells and are induced to differentiate as soon as they 
emerge from the blood stream. As they differentiate, they start expressing and 
secreting tenascin-W into the surrounding tissue. Tenascin-W in turn will influence 
the behavior of surrounding cells, for instance by enhancing the motility of 
endothelial cells and thus contribute to the extension of the tumor blood vessel 
network. 
As hypothetical this interpretation is at the moment, it could prompt and guide future 
investigations, as it remains to be established whether MSC differentiation other 
than to osteoblasts triggers tenascin-W expression.     
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V. APPENDIX 
 
V.1 Experimental procedures (unpublished results) 
 
SEAP constructs 
Plasmids pGL3-TNW-2000bp, pGL3-TNW-1000bp, pGL3-TNW-500bp, pGL3-TNW-
350bp, and pGL3-TNW-250bp, containing various lengths of the human tenascin-W 
promoter inserted in the pGL3-basic vector (Promega) were obtained from Dr. 
Martin Degen. The inserts were excised by digestion with NheI and XhoI and 
directionally cloned in the MCS of pSEAP2-basic (Clontech), generating the 
plasmids pSEAP-TNW(-1800), pSEAP-TNW(-957), pSEAP-TNW(-512), pSEAP-
TNW(-252), and pSEAP-TNW(-148).  
 All successive PCR reactions were performed using the Expand High Fidelity PCR 
System (Roche) and plasmid pSEAP-TNW(-512) as template. Reverse primer 5’-
AGAAGTCCGGGTTCTCCTCCTCA-3’ was used together with forward primer 5’-
TTTGCTAGCGCTCATTTCTTTCTGTGCTAAAGG-3’ or forward primer 5’- 
TTTGCTAGCCACTTTTGAACCCCGAGACCCAG-3’; the resulting amplicons were 
digested with NheI and XhoI and cloned in pSEAP2-basic to obtain pSEAP-TNW(-
319) and pSEAP-TNW(-252) respectively.  
The plasmids with internal deletions were obtained as follows. In the first set of PCR 
reactions, the forward primer listed in Table 1 (upper section) was used together 
with the common reverse primer mentioned above, while the common forward 
primer 5’-GGTACCGAGCTCTTACGCGT-3’ was used with the appropriate reverse 
primer listed in Table 1. The corresponding partially overlapping PCR products were 
gel purified, mixed at equimolar ratio and annealed by slowly cooling from 95°C to 
55°C in 10 min. The second set of PCR used the common forward primer and the 
common reverse primer to amplify the partially overlapping amplicons annealed in 
the previous step. The PCR products were digested with NheI and XhoI and cloned 
in pSEAP2-basic to obtain the plasmid listed in Table 1. The construct pSEAP-
TNW(-512)MUT was obtained by site directed mutagenesis using the following 
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primers: forward primer 5’-GCTCATCTCGTTTTAGCAGAGTCCCTG-3’; reverse 
primer 5’- CTAAAACGAGATGAGCAATTCCTTC-3’ (mutated bases are underlined). 
 
 
Table V.1 – Primers used in this study 
 
Cell culture and transfection 
HT1080 (ATCC #CCL-121), Saos-2 (ATCC #HTB-85), KRIB ( ) and U2OS (ATCC 
#HTB-96) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FCS, 2mM/l glutamine and antibiotics (100 U/ml penicillin; 
100 μg/ml streptomycin). Cells were plated in 12-well plates at a density of 50000 
cells/well, in growth medium. The next day, at cell confluence of about 60-70%, the 
medium was exchanged with DMEM 0.3% FCS and the cells were transfected by 
JetPEI (Polyplus) with 0.6 µg/well of total DNA (pSEAP reporter construct and 
pMetLuc for normalization mixed at 1:20 molar ratio). After 48h in cultures, an 
Cloning Forward primer (5’-3’) Reverse primer (5’-3’) 
pSEAP-TNW(-512)∆-423/-319 TGAGGGTCTCTCACTTTTGAACCCCGAGA TTCAAAAGTGAGAGACCCTCAGGGACAGAA 
pSEAP-TNW(-512)∆-319/-252 CTTTATAAATGGGATTCACTTAAATGGAAAC TAAGTGAATCCCATTTATAAAGTTTCTTTCTCTT 
pSEAP-TNW(-512)∆-252/-148 CCTTATTCTGAGAAGGAATTGCTCATTATC ATTCCTTCTCAGAATAAGGATATTAAAAG 
pSEAP-TNW(-512)∆-148/-79 GTTAGAATAATTTGCTCCTCCTCTGGCCTAG AGGAGCAAATTATTCTAACTAGGAAAGAAA 
pSEAP-TNW(-512)∆-79/-59 AGGAGTCTCCAGACAGGATTTAAACCCAGGA AAATCCTGTCTGGAGACTCCTGGTGTTTTCC 
pSEAP-TNW(-512)∆-59/-34 GGCCTAGACAAAGCCAAGGAGAGACGAGAAC TCCTTGGCTTTGTCTAGGCCAGAGGAGGAGC 
pSEAP-TNW(-512)∆-34/+27 CCAGGAAGGGACCGGCTCACAGGAGCAGCAG GTGAGCCGGTCCCTTCCTGGGTTTAAATCC 
pSEAP-TNW(-512)∆+1/+78 GACGACCAGCCTCGAGATCTGCGATCTAAG CAGATCTCGAGGCTGGTCGTCCCTGGTTCT 
pSEAP-TNW(-512)∆-148/-136 AGTTAGAATAACTCATTATCTTTTAGCAGAGT AGATAATGAGTTATTCTAACTAGGAAAGAAAAA 
pSEAP-TNW(-512)∆-136/-122 GAGAAGGAATTGGCAGAGTCCCTGCTAGGAAGGG AGGGACTCTGCCAATTCCTTCTCTTATTCTAACTA 
pSEAP-TNW(-512)∆-122/-100 TATCTTTTAAGGAAAACACCAGGAGTCT TGTTTTCCTTAAAAGATAATGAGCAATTC 
pSEAP-TNW(-512)∆-100/-79 TAGGAAGGGTTTGCTCCTCCTCTGGCCT AGGAGCAAACCCTTCCTAGCAGGGACTCTGCTA 
   qPCR     
TNW ATGCCCTCACAGAAATTGACAG TCTCTGGTCTCTTGGTCGTC 
ALPL GCTGGCAGTGGTCAGATGTT CTATCCTGGCTCCGTGCTC 
TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
   ChIP     
TNW -425/-215 CTCTGCTCATTTCTTTCTGTGCTA GCTAAAAATACTGGAGGCTGTTTC 
TNW Ex10-11 CTCTTCCTCCAGGGGCTTAC GACATGGTCTCTGCTCACCA 
LINE TTCCAGGCAAGAATCAACAA CTTGGACCACTTGGTTAGGG 
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aliquot of conditioned medium was collected, centrifuged max speed for 1 min and 
used directly for SEAP or MetLuc assays. 
 
Reporter gene assay 
The measurement of the amount of alkaline phosphatase in the culture medium was 
performed using the SEAP Reporter Gene Assay kit (Roche), following the protocol 
of the manufacturer. Ready-To-Glow secreted luciferase reporter system (Clontech) 
was used for the luciferase quantification in the culture medium, according to the 
instructions of the manufacturer. Chemiluminescence levels were read with a 
luminometer Mithras LB940 (Berthold technologies). SEAP luminescence values of 
each sample were divided by the corresponding luciferase luminescence values, to 
obtain the normalized SEAP luminescence. Although different combinations of 
SEAP constructs were transfected in triplicate in different experiments, the plasmid 
pSEAP-TNW(-512) was included in all experiment and was thus used as a calibrator 
to compare different experiments. Normalized SEAP luminescence of each sample 
of each experiment was divided by the pSEAP-TNW(-512) normalized SEAP 
luminescence of the same experiment, to obtain the normalized relative SEAP 
activity. The geometric mean of the normalized relative SEAP activities among all 
the experiments is displayed in the graphs. Error bars are standard error of the 
mean among all the replicates considered. Mann-Whitney U test was performed to 
test the statistical significance of the results when indicated. 
 
In silico analysis for conserved sequences and transcription factor binding 
sites 
The genomic location of the human tenascin-W gene was examined using the 
UCSC genome browser (http://genome.ucsc.edu/) and the ECR browser 
(http://ecrbrowser.dcode.org/). To look for predicted transcription factor binding sites 
in the genomic sequence, we used MatInspector (http://www.genomatix.de) and 
rVISTA 2.0 (http://rvista.dcode.org/). 
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DNA pull-down 
Approximately 8 x 107 HT1080 cells were harvested in cold PBS by scraping the 
culture dishes with a rubber policeman. Cells were spun at 400 x g for 5 min at 4°C 
and the pellet was resuspended in lysis buffer (10 mM HEPES; 15 mM KCl; 2 mM 
EDTA; 0.5 mM spermidine; 0.15 mM spermine; 0.5% NP-40; 1 mM DTT, 0.4 mM 
Pefabloc SC [Roche]; complete protease inhibitors cocktail [Roche]). After 5 min 
incubation on ice, cells were vortexed (complete cell lysis was confirmed at the 
microscope after staining a drop of lysate with Tripan-blue). To separate the intact 
nuclei from cytoplasm and membrane debris, the suspension was spun at 1900 x g 
for 20 min at 4 °C through a sucrose cushion (lysis buffer with addition of 0.88 M 
sucrose). The nuclei pellet was resuspended in nuclear lysis buffer (10 mM HEPES; 
550 mM KCl; 0.1 mM EDTA; 10% glycerol; 3 mM MgCl2; 1 mM DTT; 0.4 mM 
Pefabloc SC; complete protease inhibitors cocktail) and incubated under rotation for 
30 min at 4 °C. After 20 min centrifugation at 5000 x g at 4 °C, the supernatant was 
collected and stored at -80 °C. The 5’-biotinylated forward oligo 5’-
AGAGAAGGAATTGCTCATTATCTTTTAGCAG-3’ and the unlabeled reverse 5’- 
CTGCTAAAAGATAATGAGCAATTCCTTCTCT-3’ were annealed to obtain the 
biotinylated probe WT; 5’-biotinylated forward oligo 5’- 
AGAGAAGGAATTGCTCATCTCGTTTTAGCAG-3’ and the unlabeled reverse 5’- 
CTGCTAAAACGAGATGAGCAATTCCTTCTCT-3’ were annealed to obtain the 
biotinylated probe MUT, containing the underlined mutation. Corresponding 
unlabeled probes were obtained by annealing unlabeled oligos.  
Nuclear extract was diluted in 2.6 volumes of nuclear dilution buffer (27.7 mM Tris-
HCl pH 8; 1.35 mM EDTA; 16.9% glycerol; 0.07% NP-40; 1 mM DTT; 0.4 mM 
Pefabloc SC; complete protease inhibitors cocktail) and 600 ng were incubated with 
approximately 10 µg of biotinylated probe (WT or MUT), 50 µg of competitor 
unlabeled probe (MUT or WT, respectively), 100 µg of poly[d(I-C)] (Roche) in 
binding buffer (20 mM Tris-HCl pH 8; 150 mM KCl; 1 mM EDTA; 15% glycerol; 
0.05% NP-40; 1 mM DTT; 0.4 mM Pefabloc SC; complete protease inhibitors 
cocktail). A control sample was incubated with a 1:1 mixture of unlabeled probe and 
omitting the biotinylated probe (ctr). After 1 hour of rotation at 4 °C, 30 µL of 
previously washed Streptavidin Magnespheres paramagnetic particles (Promega) 
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equilibrated in binding buffer were added to the suspension, and the mixture was 
further incubated for 1 hour. The paramagnetic particles were then washed four 
times for 5 min in binding buffer at room temperature. The elution step consisted in 
1 hour incubation at room temperature in presence of 100 µg of the corresponding 
unlabeled probe in binding buffer. The supernatant was collected, subjected to TCA 
precipitation and submitted to mass spectrometry analysis. 
 
Mass spectrometry 
The eluted proteins were precipitated with TCA followed by acetone washing of the 
protein pellets. The proteins were reduced with TCEP, alkylated with iodoacetamide 
and cleaved with trypsin. Peptides were injected onto a reversed phase column for 
liquid chromatography-tandem mass spectrometry (LC-MSMS) analysis in the 
information-dependent acquisition mode. Electrospray ionization LC-MSMS was 
performed using a Magic C18 HPLC column (75 μm × 10 cm; Swiss BioAnalytics) 
with a 1200 Nano-HPLC system (Agilent Technologies) connected to a LTQ 
Orbitrap Velos (Thermo Scientific). The peptides were loaded onto a peptide 
captrap (Michrom BioResources) at a flow rate of 10 μl/min for 5 minutes in buffer A 
(H2O/acetonitrile/formic acid/trifluoroacetic acid, 98/2/0.1/0.005, v/v/v/v). They were 
eluted at a flow rate of 400 nl/min with a linear gradient of B (acetonitrile/H2O/formic 
acid/trifluoroacetic acid, 80/20/0.1/0.005, v/v/v/v) in A as follows: 0–10% in 3 min, 
10-40% in 80 min, 40-55% in 10 min, 55%-100% in 2 min followed by a 2 min flush 
of 100% B. Information-dependent acquisition analyses were done according to the 
manufacturer's recommendations, i.e. 1 survey scan at 60K resolution in the 
Orbitrap cell was followed by 20 product ion scans in the linear ion trap, and 
precursors were excluded for 15 second after their second occurrence. Individual 
MSMS spectra, containing sequence information were compared with the program 
Mascot against the protein sequence database Swiss-Prot 2010_09 (Perkins et al 
1999). Carboxyamidomethylation of cystein (+57.0245) was set as a fixed 
modification and oxidation of methionine (+15.9949 Da),   acetylation of the protein 
N-terminus (+42.0106), deamidation of asparagine and glutamine (-0.9840) and 
glutamine to pyroglutamic acid (-17.0265) were selected as variable modifications. 
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Parent tolerance was 5 PPM and fragment tolerance 0.6 Da. Quantitative analyses 
of the peptides were done with the program ProgenesisLC (Nonlinear). 
 
qPCR 
Total RNA or mRNA was extracted using the RNeasy kit (QIAGEN) or Dynabeads 
mRNA Direct kit (Invitrogen), respectively. 0.2-1 µg of RNA was reverse transcribed 
to cDNA using High Capacity cDNA Reverse Transcription kit (Applied Biosystem), 
and the cDNA was diluted 1:6. The PCR reactions were performed using a StepOne 
Plus qPCR system (Applied Biosystems) in 20 µL total volume on 5 µL of diluted 
cDNA, using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and the gene 
specific primers listed in Table V.1 (middle section). The raw fluorescence data were 
exported and analyzed using Miner (http://www.ewindup.info/miner/version2/). Tata-
BOX binding protein (TBP) was considered as housekeeping gene for normalization 
purposes. 
 
Antibodies 
Anti-tenascin-W mAb 56O (35) was used for immunofluorescence at 1:50 dilution. 
The antibodies employed in ChIP are rabbit anti-CHD4 pAb (cat #ab72418, Abcam), 
rabbit anti-SUZ12 mAb (cat #D39F6, Cell Signalling), anti-mouse-IgG rabbit serum 
(Lot No. 0111-0082, cat #29204, Cappel Organon Teknika). 
 
Chromatin immunoprecipitation 
A total of 4 x 107 HT1080 cells were harvested for each experiment. One volume of 
formaldehyde buffer (50 mM HEPES pH=8.0, 1 mM EDTA, 0.5 mM EGTA, 100 mM 
NaCl, 11% formaldehyde) was added to ten volumes of culture medium, and the 
cells were incubated at room temperature for 10 min. To stop the cross-linking, 
0.125 M glycine was added, and the incubation was continued on ice for 10 min. All 
procedures were carried out at 0 to 4°C unless specifically stated otherwise. Cells 
were rinsed twice with PBS, then collected using a rubber policeman and 
resuspended in PBS containing protease inhibitors (complete mini, EDTA-free 
protease inhibitors cocktail tablets, Roche). The cells were washed once in wash 
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buffer 1 (10 mM Tris pH=8.0, 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100), 
washed twice in wash buffer 2 (10 mM Tris pH=8.0, 1 mM EDTA, 0.5 mM EGTA, 
200 mM NaCl), and resuspended in lysis buffer (50 mM HEPES/KOH pH=7.5, 500 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% deoxycholic acid, 0.1% SDS, and 
protease inhibitors) and incubated 10 min. After shearing the DNA by sonication, the 
lysate was clarified by centrifugation (at 14000 x g for 10 min) and then pre-
incubated with a mixture of protein-A (75%) and protein-G (25%) magnetic beads 
(Dynabeads, Invitrogen), previously blocked with 1 mg/mL BSA and 500 µg/mL of 
tRNA. The clarified chromatin was divided in 70 µg aliquots (ca 500 µL) for 
immunoprecipitation (IP). After the addition of 1 to 10 μg of antibody and overnight 
incubation, 20 μl of protein-A/protein-G blocked magnetic beads were added to the 
lysate and mixed by rotation for an additional 3 h. the beads were washed twice with 
1 mL of Lysis buffer without protease inhibitors with rotation for 5 min, once with 
DOC buffer (10 mM Tris pH=8.0, 0.25 LiCl, 0.5% NP-40, 0.5% deoxycholic acid, 1 
mM EDTA), and then once with TE buffer. Protein-DNA cross-linked material was 
then eluted by vortexing in 150 μl of elution buffer (100 mM NaHCO3, 1% SDS) at 
room temperature for 15 min. After the beads were pelleted by centrifugation (14000 
x g for 2 min at room temperature) a second elution was performed and eluates 
were pooled.    
The procedure to reverse cross-linking consisted in a preliminary incubation for 30 
min at 37°C with 0.2 mg/mL RNase A, followed by addition of 10 mM EDTA, 40 mM 
Tris pH=6.5, 50 µg/mL Proteinase K to the IP fraction, or 1% SDS, 100 mM NaCl, 
200 µg/mL Proteinase K to the Input fraction, and incubated 3 h at 55°C and 
overnight at 65°C. The DNA was purified using a QIAquick PCR purification kit 
(Qiagen) and then subjected to real-time quantitative PCR assay with SYBR green. 
PCR assays were performed in triplicate from two independent 
immunoprecipitations. The abundance of specifically immunoprecipitated DNA 
relative to input was calculated from the CT values for the samples, and the 
amplification efficiency was determined using Miner. The PCR primers used are 
shown in Table V.1 (lower section). 
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Primary BMSC culture and differentiation 
Bone marrow-derived mesenchymal stem cells (BMSC), isolated from three patients 
(#169, #184 and #199), expanded to P3 and frozen, were obtained from Dr. Arnaud 
Scherberich (University Hospital of Basel). Cells were cultured in α-MEM containing 
10% FCS, 1% HEPES, 1% sodium pyruvate, 10 mM glutamine (control medium), 
supplemented with 5 ng/mL FGF2. Osteogenic differentiation medium consisted of 
control medium supplemented with 100 nM dexamethasone (cat #D-2915, Sigma), 
10 mM β-glycerophosphate (cat #G-9891, Sigma), and 100 µM ascorbic acid 2-
phosphate (cat #A-8960, Sigma). Medium was exchanged every second day. To 
test for osteogenic differentiation, cells were washed with PBS, fixed for 10 min with 
Formal-fixx (Thermo-Scientific) at RT, and washed twice with PBS. Cells were then 
incubated 2 min at RT in alkaline phosphatase activity staining solution (one 
SIGMAFAST BCIP/NBT tablet [cat #B5655, Sigma] dissolved in 10 mL H2O). After 
three washes in PBS, pictures of stained cells were acquired with a Nikon Eclipse 
80i microscope equipped with a Leica DFC420 color camera.  
 
Immunofluorescence 
Cells were cultured on 8-chambers slide (cat #354108, BD Falcon) either in control 
or in osteogenic medium, for the indicated amount of time. Cells were then fixed for 
10 min in Formal-fixx (Thermo-Scientific) at RT, rinsed with PBS and additionally 
fixed for 10 min in methanol at -20°C. After 30 min blocking at RT in blocking buffer 
(PBS/0.01%Tween, 1% BSA), cells were incubated O/N at 4°C in blocking buffer 
containing the primary antibody. After three washes in PBS, cells were incubated for 
one hour at RT in PBS/0.01%Tween containing the Alexa-488-conjugated 
secondary antibody (1:200) and Hoechst (1:2000). Cells were then washed three 
times with PBS and mounted in ProLong Gold Antifade reagent (Invitrogen). 
Pictures were acquired using a Zeiss Axioimager Z1 connected to an AxioCam 
MRm and processed with ImageJ. 
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V.2 Supplementary data 
 
Figure V.2.1 – Correlation between tenascin-W and tenascin-C and tumor grade in lung cancer 
samples. Sixty-nine kidney tumor samples, spotted on a frozen TMA were stained for of tenascin-W 
and tenascin-C. The area of the section stained for tenascin-W or tenascin-C was quantified as 
described in Section III.2.1 - Materials and Methods. Samples were grouped according with the 
tumor grade and the percentage of staining for each sample was plotted as a spot. Asterisks indicate 
p < 0.05 in a non parametric group test. 
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